BioCentury | Feb 22, 2019
Company News

China approves Solasia's oral mucositis product

...U.S., Europe and Japan. Solasia has exclusive rights to Episil in Japan and China from Camurus AB...
...Episil in most of China, while Solasia retains rights in Beijing, Shanghai, Guangzhou and Taiwan. Camurus...
...off SEK2 to SEK67.30 on Thursday. Lee's added HK$0.05 to HK$6.46. Hongjiang Li episil (SP-03, episil oral spray) Camurus AB Lee's...
BioCentury | Feb 22, 2019
Clinical News

China approves Solasia's oral mucositis product

...U.S., Europe and Japan. Solasia has exclusive rights to Episil in Japan and China from Camurus AB...
...Episil in most of China, while Solasia retains rights in Beijing, Shanghai, Guangzhou and Taiwan. Camurus AB...
...Solasia Pharma K.K. (Tokyo:4597), Tokyo, Japan Product: Episil (SP-03) Business: Neurology Hongjiang Li episil (SP-03, episil oral spray) Camurus AB Lee's...
BioCentury | Jan 4, 2019
Clinical News

‘Tentative’ FDA approval for Braeburn's opioid addiction product

...dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. Partner Camurus AB...
...syringe containing a lipid solution of buprenorphine with Camurus' FluidCrystal injection depot technology. Braeburn and Camurus...
...FluidCrystal injection depot technology. Braeburn and Camurus both announced the news on Sunday, Dec. 23. Camurus...
BioCentury | Dec 26, 2018
Company News

‘Tentative’ FDA approval for Braeburn's opioid addiction product

...dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. Partner Camurus AB...
...syringe containing a lipid solution of buprenorphine with Camurus' FluidCrystal injection depot technology. Braeburn and Camurus...
...FluidCrystal injection depot technology. Braeburn and Camurus both announced the news on Sunday, Dec. 23. Camurus...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...Tokyo:3407) Preob Osteonecrosis of the hip Interim Ph III data 4Q18 Braeburn Pharmaceuticals Inc. / Camurus AB...
BioCentury | Sep 28, 2018
Clinical News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

...Medicines Co. traded down $0.74 to $33.75 Sept. 21. The committee recommended Buvidal buprenorphine from Camurus AB...
...prefilled syringe contains a lipid solution of buprenorphine with Camurus' Fluid Crystal injection depot technology. Camurus...
...Co. (NYSE:LLY), Indianapolis, Ind. The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. Sarepta Therapeutics (NASDAQ:SRPT), Cambridge, Mass. Camurus AB...
BioCentury | Sep 21, 2018
Company News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

...meropenem. Medicines Co. traded down $0.74 to $33.75 Friday. The committee recommended Buvidal buprenorphine from Camurus AB...
...prefilled syringe contains a lipid solution of buprenorphine with Camurus' Fluid Crystal injection depot technology. Camurus...
...Compound #), AMG 761 (Compound #), mogamulizumab (Generic), Poteligeo (Other) Vabomere (Brand), Carbavance (Former), meropenem/vaborbactam (Generic) Biocon Ltd. Camurus AB Eli...
BioCentury | Sep 21, 2018
Clinical News

Braeburn’s CAM2038 meets in Phase III for chronic low back pain

...incorporates FluidCrystal injection depot technology from Camurus AB (SSE:CAMX). Braeburn has exclusive rights to CAM2038 from Camurus...
...as well as option rights in some Asian territories. Braeburn Pharmaceuticals Inc., Plymouth Meeting, Pa. Camurus AB...
...opioid receptor (MOR; OPRM1) Description: Ready-to-use prefilled syringe containing a lipid solution of buprenorphine with Camurus'...
BioCentury | Jul 20, 2018
Clinical News

FDA again reviewing Braeburn's opioid addiction candidate

...incorporates FluidCrystal injection depot technology from Camurus AB (SSE:CAMX). Braeburn has exclusive rights to CAM2038 from Camurus...
BioCentury | Jul 16, 2018
Company News

FDA again reviewing Braeburn's opioid addiction candidate

...CAM2038 from Camurus in North America as well as option rights in some Asian territories. Camurus...
...development and use of medication-assisted treatments (MATs) (see "Turning the Tide" ). Paul Bonanos CAM2038, buprenorphine Braeburn Pharmaceuticals Inc. Camurus AB...
Items per page:
1 - 10 of 43
BioCentury | Feb 22, 2019
Company News

China approves Solasia's oral mucositis product

...U.S., Europe and Japan. Solasia has exclusive rights to Episil in Japan and China from Camurus AB...
...Episil in most of China, while Solasia retains rights in Beijing, Shanghai, Guangzhou and Taiwan. Camurus...
...off SEK2 to SEK67.30 on Thursday. Lee's added HK$0.05 to HK$6.46. Hongjiang Li episil (SP-03, episil oral spray) Camurus AB Lee's...
BioCentury | Feb 22, 2019
Clinical News

China approves Solasia's oral mucositis product

...U.S., Europe and Japan. Solasia has exclusive rights to Episil in Japan and China from Camurus AB...
...Episil in most of China, while Solasia retains rights in Beijing, Shanghai, Guangzhou and Taiwan. Camurus AB...
...Solasia Pharma K.K. (Tokyo:4597), Tokyo, Japan Product: Episil (SP-03) Business: Neurology Hongjiang Li episil (SP-03, episil oral spray) Camurus AB Lee's...
BioCentury | Jan 4, 2019
Clinical News

‘Tentative’ FDA approval for Braeburn's opioid addiction product

...dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. Partner Camurus AB...
...syringe containing a lipid solution of buprenorphine with Camurus' FluidCrystal injection depot technology. Braeburn and Camurus...
...FluidCrystal injection depot technology. Braeburn and Camurus both announced the news on Sunday, Dec. 23. Camurus...
BioCentury | Dec 26, 2018
Company News

‘Tentative’ FDA approval for Braeburn's opioid addiction product

...dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. Partner Camurus AB...
...syringe containing a lipid solution of buprenorphine with Camurus' FluidCrystal injection depot technology. Braeburn and Camurus...
...FluidCrystal injection depot technology. Braeburn and Camurus both announced the news on Sunday, Dec. 23. Camurus...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...Tokyo:3407) Preob Osteonecrosis of the hip Interim Ph III data 4Q18 Braeburn Pharmaceuticals Inc. / Camurus AB...
BioCentury | Sep 28, 2018
Clinical News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

...Medicines Co. traded down $0.74 to $33.75 Sept. 21. The committee recommended Buvidal buprenorphine from Camurus AB...
...prefilled syringe contains a lipid solution of buprenorphine with Camurus' Fluid Crystal injection depot technology. Camurus...
...Co. (NYSE:LLY), Indianapolis, Ind. The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. Sarepta Therapeutics (NASDAQ:SRPT), Cambridge, Mass. Camurus AB...
BioCentury | Sep 21, 2018
Company News

CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere

...meropenem. Medicines Co. traded down $0.74 to $33.75 Friday. The committee recommended Buvidal buprenorphine from Camurus AB...
...prefilled syringe contains a lipid solution of buprenorphine with Camurus' Fluid Crystal injection depot technology. Camurus...
...Compound #), AMG 761 (Compound #), mogamulizumab (Generic), Poteligeo (Other) Vabomere (Brand), Carbavance (Former), meropenem/vaborbactam (Generic) Biocon Ltd. Camurus AB Eli...
BioCentury | Sep 21, 2018
Clinical News

Braeburn’s CAM2038 meets in Phase III for chronic low back pain

...incorporates FluidCrystal injection depot technology from Camurus AB (SSE:CAMX). Braeburn has exclusive rights to CAM2038 from Camurus...
...as well as option rights in some Asian territories. Braeburn Pharmaceuticals Inc., Plymouth Meeting, Pa. Camurus AB...
...opioid receptor (MOR; OPRM1) Description: Ready-to-use prefilled syringe containing a lipid solution of buprenorphine with Camurus'...
BioCentury | Jul 20, 2018
Clinical News

FDA again reviewing Braeburn's opioid addiction candidate

...incorporates FluidCrystal injection depot technology from Camurus AB (SSE:CAMX). Braeburn has exclusive rights to CAM2038 from Camurus...
BioCentury | Jul 16, 2018
Company News

FDA again reviewing Braeburn's opioid addiction candidate

...CAM2038 from Camurus in North America as well as option rights in some Asian territories. Camurus...
...development and use of medication-assisted treatments (MATs) (see "Turning the Tide" ). Paul Bonanos CAM2038, buprenorphine Braeburn Pharmaceuticals Inc. Camurus AB...
Items per page:
1 - 10 of 43